A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | MicrobiomeTrials← Back to trialsNCT05544929
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2022-10-26Est. Completion: 2027-10-05
Enrollment target: 126 participants Locations- Massachusetts General Hospital ., Boston, Massachusetts, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- NYU School of Medicine, New York, New York, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- Novartis Investigative Site, Toronto, Ontario, Canada
- Novartis Investigative Site, Guangzhou, Guangdong, China
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Lyon, France
- Novartis Investigative Site, Dresden, Saxony, Germany
- Novartis Investigative Site, Essen, Germany
- Novartis Investigative Site, Hong Kong, Hong Kong
- Novartis Investigative Site, Milan, MI, Italy
- Novartis Investigative Site, Chuo Ku, Tokyo, Japan
- Novartis Investigative Site, Singapore, Singapore
- Novartis Investigative Site, Seoul, Seoul, South Korea
- Novartis Investigative Site, Barcelona, Spain
Other microbiome trials you might be interested in
Lung NeoplasmsNeoadjuvant TherapyImmunotherapyMinimal Residual Disease
This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (…
Beijing, ChinaEst. completion Oct 31, 2027
Non-small Cell Lung Cancer Stage IV
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non…
Banja Luka, Bosnia and HerzegovinaEst. completion Mar 10, 2026
Novartis Investigative Site, Taipei, TaiwanNon-small Cell Lung Cancer
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participa…
Bakersfield, United StatesEst. completion Jan 24, 2028